SBIR/STTR Research Award

Development of LAMP-Comet and Immuno-Comet Assays

Award identifier f34278c54e029591063d36f435cbd2d00dbfc7a72d4ae305f4c3e5566bf784fdAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$291,838

Program and phase

SBIR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
TREVIGEN, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The single cell gel electrophoresis (SCGE) or Comet assay, is now internationally recognized as a simple and inexpensive method for the detection of different types of DNA damage, including single- and double- strande d breaks, DNA adducts, cross-links, and alkaline-labile sites in a low throughput format. For the Comet assay, cells are suspended in molten low melting point agarose and layered onto a microscope slide. The cells are then lysed with high salt and detergen t, and the liberated DNA is subjected to alkaline or neutral electrophoresis. Damaged DNA is then detected by its altered migration towards the anode. The individual pattern of DNA migration per cell is called the Comet and is easily visualized by staining with an appropriate fluorescent dye. The Comet assay can be modified for specific applications including detection of acute or chronic genotoxicity, cellular responses to DNA damage, biomonitoring, cancer risk assessment, and cancer cell resistance to tre atment. Two important customized applications for the Comet assay are the detection of cell-marker- and gene- specific DNA damage. The former application utilizes immunofluorescence followed by a Comet assay, and can be invaluable for the screening of drug s that are selectively genotoxic to tumors bearing specific markers, including those produced by tumor viruses. Similarly, assessment of gene-specific damage is useful for the understanding of the effects of replication and transcription on genotoxicity. U sing fluorescence in situ hybridization (FISH), the Comet assay can detect and identified DNA sequences undergoing repair. Currently, the protocols for both of these assays have difficulties associated with them. However, the interest in Comet-FISH has inc reased despite the difficulty associated with this assay. Aim 1 will therefore be to develop a new in situ detection protocol for visualization of newly repaired genes in the Comet assay using loop-mediated amplificatiion (LAMP). Aim 2 will be to develop a new immunostaining method for simultaneous visualization of specific antigens and DNA damage using Quantum Dot Technology. The development of such assays addresses needs to allow rapid analysis of gene and protein-specific DNA damage.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.